Tango Therapeutics (TNGX) Net Margin (2020 - 2025)

Tango Therapeutics' Net Margin history runs 6 years deep, the most recent figure standing at 29.52% for Q3 2025.

• In Q3 2025, Net Margin rose 28081.0% year-over-year to 29.52%; the TTM figure through Mar 2026 stood at 188.08% (up 13447.0% YoY), while the FY2025 annual figure was 162.85%, up 14686.0% from the prior year.
• Net Margin was 29.52% for Q3 2025 at Tango Therapeutics, up from 1221.41% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 29.52% in Q3 2025 to a low of 1221.41% in Q2 2025.
• Historically, Net Margin has averaged 411.69% across 5 years, with a median of 419.8% in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Margin surged 28887 bps in 2023, then plunged 109285 bps in 2025.
• A 5-year view of Net Margin shows it stood at 385.69% in 2021, then declined by 18 bps to 453.28% in 2022, then declined by 25 bps to 566.43% in 2023, then slumped by 61 bps to 913.8% in 2024, then soared by 103 bps to 29.52% in 2025.
• The last three Net Margin figures came in at 29.52% (Q3 2025), 1221.41% (Q2 2025), and 739.54% (Q1 2025), per Business Quant data.